Leap Therapeutics Faces Financial Challenges Amid Stock Drop Leap Therapeutics has hit a 52-week stock low of $0.4, reflecting an 85% decline in value this year. Despite positive data for its colorectal cancer drug, the company faces hurdles, including discontinued gastric cancer trials. Analysts have downgraded its stock, citing financial concerns and uncertain market potential.34